Fig. 2: RhmAb specificities and function.

a, Schematic representation of RhmAbs used in this study. ITS09.01-LS, ITS102.01-LS, ITS103.01-LS and ITS113.01-LS RhmAbs target V2, CD4 binding site, CD4 binding site proximal and MPER, respectively. b, Surface binding of RhmAbs to SIV_mac239-infected A66 cells. The percentage of infected cells (p27⁺) with bound RhmAbs (at 10 µg ml⁻¹ and 1 μg ml⁻¹) was measured by flow cytometry. Combo indicates the binding of a combination of all four RhmAbs (total of 40 µg ml⁻¹ and 4 μg ml⁻¹). Anti-DSP was used as a negative control at both 40 µg ml⁻¹ and 4 µg ml⁻¹. Technical replicates are shown: n = 5 (10 µg ml⁻¹); n = 4 (1 μg ml⁻¹ and combo at 10 µg ml⁻¹ each); n = 3 (combo at 1 μg ml⁻¹ each); n = 7 (DSP 40 µg ml⁻¹); n = 9 (DSP 4 µg ml⁻¹). Mean with 95% confidence intervals are shown. c, In vitro analysis of ICE ADCC assay using SIV_mac239-infected or mock-infected A66 cells as targets and NK92RhCD16 cells as effectors at a 10:1 effector:target ratio. Individual RhmAbs were tested using five-fold dilutions starting at 100 µg ml⁻¹ concentration. The cocktail of four RhmAbs was also tested starting with 80 µg ml⁻¹ total IgG (20 µg ml⁻¹ of each RhmAb). The negative control DSP was tested using five-fold dilutions starting at 80 µg ml⁻¹. d, In vitro analysis of ADNP using granulocytes isolated from PBMCs of SIV_mac239-infected RMs as effectors and SIV_mac239 gp130-coated fluorescent beads as targets. Individual RhmAbs were tested using 100 µg ml⁻¹ concentration. Combined RhmAbs were tested using 100 µg ml⁻¹ concentration of each RhmAb. The negative control DSP was tested at 100 µg ml⁻¹ and 400 µg ml⁻¹ (DSP100 and DSP400). e, RhmAb concentrations in serum (mean ± s.e.m.) are shown after each of the two injections of RhmAbs over10 weeks of the intervention phase of the experiment. Vertical blue lines show the timing of RhmAb administration. f, Half-life (T_1/2) of RhmAbs after the first dose. RhmAb controls (n = 6), RhmAb + AZD5582 (n = 9) and RhmAb + AZD5582 + N-803 (n = 9). g, AUC of RhmAb concentrations from 24 h after the first dose through day 70. RhmAb controls (n = 6), RhmAb + AZD5582 (n = 9) and RhmAb + AZD5582 + N-803 (n = 9). Statistical significance was determined using the Kruskal–Wallis test with Dunn’s multiple comparisons test in f and g. Horizontal lines represent the median. NS, non-significant. *P < 0.05; **P < 0.01; ***P < 0.001.